Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Author's Avatar
Jan 17, 2023
  • Study successfully identified lowest effective dose
  • 1.0% formulation reached primary endpoint with statistical significance
  • Company preparing for End of Phase 2 meeting with FDA following full analysis